褪黑素在幼儿中的使用:一项系统综述
该系统综述检索9个数据库、2个临床试验注册库及参考文献,纳入2000至2025年间发表的19篇文章(12项观察性研究、6项试验、1项方案)。观察性研究显示近十年幼儿褪黑素处方、长期使用和过量暴露上升;试验纳入167例有神经系统疾病(如孤独症谱系障碍)的幼儿,平均疗程12.7周(范围2周至2年),提示睡眠潜伏期改善且不良事件少。但对其他行为与健康结局的长期数据缺失,典型发育幼儿无疗效数据。作者认为需识别策略以预防和减少幼儿褪黑素使用,并提高儿科医生对循证实践标准的依从性。
要点
- 幼儿(0-6岁)褪黑素是急诊科非监督性药物暴露和过量的首要原因。
- 观察性研究显示近十年幼儿褪黑素处方实践、长期使用和过量暴露上升。
- 6项试验纳入167例有神经系统疾病(如孤独症谱系障碍)的幼儿,平均疗程12.7周(范围2周至2年),提示睡眠潜伏期改善且不良事件少。
- 典型发育幼儿缺乏疗效数据,其他行为与健康结局的长期数据缺失。
- 纳入研究方法学质量:3项差、9项一般、6项好。
适用人群与场景
- 幼儿(0-6岁),尤其是有神经系统疾病(如孤独症谱系障碍)的幼儿。
- 观察性研究数据来自北欧或澳大利亚登记系统,以及美国和葡萄牙的中毒数据。
- 典型发育幼儿缺乏疗效数据。
红旗征与不能漏的情况
- 幼儿褪黑素是急诊科非监督性药物暴露和过量的首要原因。
- 观察性研究记录到幼儿褪黑素过量暴露上升。
研究设计与关键结果
- 系统综述纳入19篇文章:12项观察性研究、6项试验、1项方案,发表于2000至2025年。
- 观察性研究报告来自北欧或澳大利亚登记系统9年(范围3-21年)的数据,以及美国和葡萄牙的中毒数据。
- 6项试验纳入167例有神经系统疾病的幼儿,平均疗程12.7周(范围2周至2年)。
- 试验提示有神经系统疾病(如孤独症谱系障碍)的幼儿睡眠潜伏期改善,不良事件少。
- 观察性研究记录到近十年处方实践、长期使用和过量暴露上升。
- 典型发育幼儿无疗效数据,其他行为与健康结局的长期数据缺失。
- 方法学质量:3项研究差、9项一般、6项好。
证据类型、等级与局限
- 证据类型:系统综述,纳入观察性研究和试验。
- 方法学质量采用Downs and Black清单评估:3项差、9项一般、6项好。
- 局限:典型发育幼儿无疗效数据;其他行为与健康结局的长期数据缺失。
对床旁实践的改变
- 作者认为需识别策略以预防和减少幼儿褪黑素使用。
- 作者认为需提高儿科医生对循证实践标准的依从性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Melatonin is the leading cause of unsupervised medication exposure and overdose in emergency departments for young children (aged 0-6 years). Existing literature has documented the benefits of melatonin in older children (aged 7-18 years) with neurologic conditions but has yet to examine young children.
OBJECTIVE: To examine the long-term outcomes (safety and effectiveness) associated with melatonin use in young children.
EVIDENCE REVIEW: Nine databases, including Ovid MEDLINE, Embase, and Web of Science; 2 clinical trial registries; existing subject matter systematic reviews; and forward and backward citation of included articles were reviewed from inception to February 26, 2025, to identify observational and interventional studies that investigated the safety and effectiveness of exogenous melatonin on sleep in young children. Methodological quality was assessed using the Downs and Black Checklist.
FINDINGS: Nineteen articles representing 12 observational studies, 6 experimental studies (hereafter, trials), and 1 protocol published between 2000 and 2025 were included. The observational studies reported on 9 years (range, 3-21 years) of data from Nordic or Australian registries or poisoning data from the US and Portugal. The trials included 167 young children with neurologic conditions and lasted a mean of 12.7 weeks (range, 2 weeks to 2 years). For safety, observational studies documented rises in prescribing practices, extended use, and overdoses, especially in the past decade. For effectiveness, trials provided evidence for improved sleep onset in young children with neurologic conditions (eg, autism spectrum disorder), with few adverse events. However, data regarding long-term outcomes for other behaviors and health outcomes were absent, and efficacy data were not available for children with typical development. The methodological quality of included studies was poor for 3 studies, fair for 9, and good for 6.
CONCLUSIONS AND RELEVANCE: These findings suggest a global rise in prescriptions without efficacy data on use in children with typical development, underscoring the need to identify strategies to prevent and reduce melatonin use in young children, as well as to improve adherence by pediatricians to evidence-based practice standards.
参考来源
- Kracht CL, Bolamperti G, Breeden R, et al. Melatonin Use in Young Children: A Systematic Review. JAMA Netw Open. 2026. PMID: 41481289. doi:10.1001/jamanetworkopen.2025.51958
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。